12
Participants
Start Date
June 23, 2022
Primary Completion Date
March 31, 2026
Study Completion Date
January 2, 2029
Ravulizumab
"Participants will receive a weight-based loading dose of ravulizumab on Day 1, followed by weight-based maintenance treatment with ravulizumab on Day 15 and every 8 weeks (q8w) after or once every 4 weeks (q4w) depending on weight.~During the Extension Period, participants will continue to receive weight-based maintenance doses of ravulizumab IV on Day 351 and q8w or q4w, depending on weight."
RECRUITING
Research Site, Esplugues de Llobregat
RECRUITING
Research Site, Goyang-si
RECRUITING
Research Site, Marseille
RECRUITING
Research Site, Philadelphia
RECRUITING
Research Site, Washington D.C.
RECRUITING
Research Site, Gallarate
RECRUITING
Research Site, Durham
RECRUITING
Research Site, Miami
RECRUITING
Research Site, Montpellier
WITHDRAWN
Research Site, Giessen
WITHDRAWN
Research Site, Bochum
WITHDRAWN
Research Site, St Louis
RECRUITING
Research Site, Chieti
RECRUITING
Research Site, Le Kremlin-Bicêtre
WITHDRAWN
Research Site, Catania
RECRUITING
Research Site, Boston
RECRUITING
Research Site, Edmonton
RECRUITING
Research Site, Toronto
RECRUITING
Research Site, Montreal
RECRUITING
Research Site, Roma
RECRUITING
Research Site, Yokohama
Lead Sponsor
Alexion Pharmaceuticals, Inc.
INDUSTRY